Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of… Read more
Medexus Pharmaceuticals Inc (MEDXF) - Net Assets
Latest net assets as of September 2025: $52.42 Million USD
Based on the latest financial reports, Medexus Pharmaceuticals Inc (MEDXF) has net assets worth $52.42 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($149.44 Million) and total liabilities ($97.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $52.42 Million |
| % of Total Assets | 35.08% |
| Annual Growth Rate | 58.7% |
| 5-Year Change | 189.39% |
| 10-Year Change | N/A |
| Growth Volatility | 365.74 |
Medexus Pharmaceuticals Inc - Net Assets Trend (2017–2025)
This chart illustrates how Medexus Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medexus Pharmaceuticals Inc (2017–2025)
The table below shows the annual net assets of Medexus Pharmaceuticals Inc from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $52.14 Million | +71.96% |
| 2024-03-31 | $30.32 Million | +35.08% |
| 2023-03-31 | $22.45 Million | +26.17% |
| 2022-03-31 | $17.79 Million | -1.25% |
| 2021-03-31 | $18.02 Million | -47.68% |
| 2020-03-31 | $34.44 Million | -7.47% |
| 2019-03-31 | $37.22 Million | +1125.11% |
| 2018-03-31 | $3.04 Million | +134.46% |
| 2017-03-31 | $1.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medexus Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3840323900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $114.14 Million | 218.89% |
| Total Equity | $52.14 Million | 100.00% |
Medexus Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Medexus Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GAMING INNOVATION DL 1
F:GI11
|
$44.96 Million |
|
Multitude SE
LSE:0R4W
|
$44.97 Million |
|
IF Bancorp Inc
NASDAQ:IROQ
|
$44.99 Million |
|
DURECT CORP. DL-001
F:DC8A
|
$44.99 Million |
|
Gemvaxlink Co. Ltd
KQ:064800
|
$44.93 Million |
|
Thanh Cong Textile Garment Investment Trading JSC
VN:TCM
|
$44.92 Million |
|
Up Young Cornerstone Corp.
TWO:6728
|
$44.91 Million |
|
Answer Technology Co Ltd
TW:3528
|
$44.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medexus Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 30,323,000 to 52,143,000, a change of 21,820,000 (72.0%).
- Net income of 2,247,000 contributed positively to equity growth.
- New share issuances of 19,162,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.25 Million | +4.31% |
| Share Issuances | $19.16 Million | +36.75% |
| Other Changes | $411.00K | +0.79% |
| Total Change | $- | 71.96% |
Book Value vs Market Value Analysis
This analysis compares Medexus Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.93x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.65x to 0.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-03-31 | $0.27 | $1.51 | x |
| 2018-03-31 | $0.52 | $1.51 | x |
| 2019-03-31 | $2.52 | $1.51 | x |
| 2020-03-31 | $2.38 | $1.51 | x |
| 2021-03-31 | $0.94 | $1.51 | x |
| 2022-03-31 | $0.89 | $1.51 | x |
| 2023-03-31 | $1.11 | $1.51 | x |
| 2024-03-31 | $1.24 | $1.51 | x |
| 2025-03-31 | $1.62 | $1.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medexus Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.07%
- • Asset Turnover: 0.63x
- • Equity Multiplier: 3.30x
- Recent ROE (4.31%) is above the historical average (-50.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -141.39% | -29.51% | 0.80x | 5.96x | $-1.96 Million |
| 2018 | -114.64% | -34.79% | 1.08x | 3.05x | $-3.79 Million |
| 2019 | -17.53% | -19.26% | 0.30x | 3.05x | $-10.24 Million |
| 2020 | -18.11% | -8.39% | 0.43x | 5.06x | $-9.68 Million |
| 2021 | -156.87% | -35.48% | 0.54x | 8.24x | $-30.07 Million |
| 2022 | -16.18% | -3.75% | 0.55x | 7.83x | $-4.66 Million |
| 2023 | 5.44% | 1.13% | 0.67x | 7.19x | $-1.02 Million |
| 2024 | -0.71% | -0.19% | 0.73x | 5.14x | $-3.25 Million |
| 2025 | 4.31% | 2.07% | 0.63x | 3.30x | $-2.97 Million |
Industry Comparison
This section compares Medexus Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medexus Pharmaceuticals Inc (MEDXF) | $52.42 Million | -141.39% | 1.85x | $44.95 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |